AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04760561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position group
Description: Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
Study NCT05700162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photograph
Description: As soon as she starts to express her milk from the mother, on whatsapp will be asked to look at the photo of the baby sent to her for 5 minutes. She will be asked to express both breasts for 15 minutes every 3 hours.
Study NCT05700162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
Study NCT05700162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Broadcast
Description: As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
Study NCT06079970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neelde Based Confocal Laser Endomicroscopy
Description: Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)
Study NCT06079970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diagnostic bronchoscopy
Description: Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
Study NCT06079970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional diagnostic bronchoscopy
Description: Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
Study NCT05069272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bakuchiol and Ethyl Linoleate
Description: A synergistic combination of Bakuchiol and Ethyl Linoleate
Study NCT05069272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: No actives
Study NCT05700162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: She will be asked to express both breasts for 15 minutes every 3 hours. No additional action will be taken.
Study NCT05301114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker support
Description: Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
Study NCT05255809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alexander Technique + Routine Physical Therapy
Description: Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.
Study NCT05255809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
Study NCT05255809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Physical Therapy
Description: Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
Study NCT06216639 — intervention group
Intervention type: DRUG
Intervention: Bismuth Subcitrate
Description: Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
Study NCT06216639 — intervention group
Intervention type: DRUG
Intervention: Esomeprazole
Description: Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
Study NCT06216639 — intervention group
Intervention type: DRUG
Intervention: Metronidazole
Description: Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
Study NCT06216639 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
Study NCT06216639 — intervention group
Intervention type: DRUG
Intervention: Clarithromycin
Description: Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
Study NCT06216639 — intervention group
Intervention type: DRUG
Intervention: Levofloxacin
Description: Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
Study NCT06103201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study NCT06220331 — intervention group
Intervention type: DEVICE
Intervention: Intra Ocular Lens
Description: Intensity SL Intra Ocular Lens
Study NCT06193590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carevix
Description: Cervical stabilization device that uses vacuum
Study NCT06193590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tenaculum
Description: standard of care cervical stabilization device
Study NCT04011358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sleeping Monitor
Description: to evaluate obstructive sleep apnea
Study NCT05139186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Artificial intelligence
Study NCT06106464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise+6.5 h of prolonged sitting
Description: Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then sit in the chair for 6.5 hours. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
Study NCT06106464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise+2 minutes of walking breaks every 30 minutes
Description: Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 2-minute walks at 35-40% of their heart rate reserve every 30 minutes for 6.5 hours after moderate-intensity aerobic exercise. They will make a twelve interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
Study NCT06106464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise+4 minutes of walking breaks every 1-h
Description: Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 4-minute walks at 35-40% of their heart rate reserve every 1 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
Study NCT06106464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise+8 minutes of walking breaks every 2-h
Description: Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 8-minute walks at 35-40% of their heart rate reserve every 2 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
Study NCT06061861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial support for healthy foods and free home delivery
Description: Participants will receive monetary support to spend on healthy food items (e.g., vegetables and fruit) through the Instacart platform for a duration of 6 months and have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
Study NCT06061861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free home delivery
Description: Participants will have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
Study NCT04829851 — intervention group
Intervention type: DEVICE
Intervention: PROTEIN Mobile App
Description: All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.
Study NCT04829851 — intervention group
Intervention type: DEVICE
Intervention: Expert Dashboard
Description: Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
Study NCT05572775 — intervention group
Intervention type: PROCEDURE
Intervention: Quadratus lumborum (QL) block
Description: bilateral anterior subcostal quadratus lumborum block
Study NCT05572775 — intervention group
Intervention type: PROCEDURE
Intervention: Erector Spinae Plane (ESP) Block
Description: bilateral erector spinae plane block
Study NCT05880342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reboxetine Pill
Description: 8 mg
Study NCT05880342 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate Oral Product
Description: 20 mg
Study NCT06046144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence-Advanced videodermatoscopy
Description: Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.
Study NCT06046144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reflectance confocal microscopy
Description: Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.
Study NCT06046144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Super-high magnification dermoscopy
Description: Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.
Study NCT05807061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EmBARK
Description: The narrated training teaches parents about children's biases and introduces multiple strategies for addressing children's biases. Families receive children's books to help practice the strategies.
Study NCT05807061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Popular guidance
Description: The popular press articles teach parents about children's biases and guide parents about how to talk to children about race. Families receive children's books focused on race to help practice talking about race.
Study NCT05807061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice first
Description: Animal books are provided to parents to help them practice talking to their children when reading books. Then, families receive a training program about race as well as children's books about race.
Study NCT04865328 — intervention group
Intervention type: OTHER
Intervention: Overactive Bladder-Validated 8-question Screener (OAB-V8)
Description: OAB-V8 is an eight-item, self-reported questionnaire that assesses the burden of OAB and the degree of bother caused by the symptoms. Since its development as a subscale of the overactive bladder questionnaire (OAB-q), the OAB-V8 questionnaire has been used to screen for OAB and to assess OAB symptom burden and severity.
Study NCT05637918 — intervention group
Intervention type: OTHER
Intervention: Group 1 (Patients who recorded as Grade 0)
Description: When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
Study NCT05637918 — intervention group
Intervention type: OTHER
Intervention: Group 2 ( Patients who recorded as Grade 1)
Description: When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
Study NCT04897464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BGaze therapy Alzheimer
Description: BGaze Therapy is an interactive eye tracking game
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna
Description: Laxative,used for bowel preparation
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Picosulfate, Magnesium Oxide and Citric Acid
Description: Laxative used for bowel preparation
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Oral antibiotic
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: Oral antibiotic
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Oral non-absorbable antibiotic
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Description: Oral non-absorbable antibiotic
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
Study NCT03593252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cefazolin
Description: Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
Study NCT05407662 — intervention group
Intervention type: OTHER
Intervention: sMRA therapies
Description: No drug will be provided to participants. Patients follow routine clinical practice/administration.
Study NCT05861349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction study
Description: Nerve conduction study of median and ulnar nerve together with sensory comparative methods on the affected side (sides).
Study NCT05861349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound of the median nerve on the affected side (sides).
Study NCT05680441 — intervention group
Intervention type: OTHER
Intervention: Peirodontal clinical measurements and gingival crevicular fluid sampling
Description: The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.
Study NCT05214261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia
Description: Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction.
Study NCT05214261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety and efficiency of post operative analgesia between laparoscopic-assisted TAP block and epidural analgesia
Description: Patients in the TAP group will be given a laparoscopic-assisted TAP block with a total of 2mg/kg of 0.25% bupivacaine in the bilateral subcostal region into four spots of the bilateral subcostal region, two on both sides of the lateral abdomen between the anterior iliac spine and lower costal arch. The TAP block is performed after the first trocar placement before the insertion of other trocars and the beginning of the surgical intervention.~In the control group epidural catheters will be placed using landmark- and loss-of-resistance techniques while the patient is on the operating table. Infusions of 4ml/h containing 0.125% levobupivacaine and 5.5 μg/mL fentanyl will be started with a CADD Solis VIP-infusion pump at the time of anesthesia induction.
Study NCT05163626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and cognitive training program
Description: Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.